Kymera Therapeutics Inc. Stock News

KT-253 demonstrates initial clinical proof of concept in patients with tumor types shown to be sensitive in preclinical models, including responses in MCC and AML

WATERTOWN, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted

Abstract released today highlights safety, pharmacodynamic and clinical response data with additional data to be presented in a poster session on June 1, 2024

KT-621, a potent, selective, oral STAT6 degrader, demonstrated comparable or superior activity to dupilumab in preclinical studies including an asthma model shared at the ATS Annual Meeting

Abstract released today highlights safety, pharmacodynamic and clinical response data collected through February 6, 2024 cut-off date

WATERTOWN, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted

New drug approvals and pipeline progress are likely to help maintain the momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position BMRN, BPMC, IM

Kymera (KYMR) reports a narrower-than-expected loss in the first quarter. The company expects the current cash balance to provide a runway into the first half of 2027.

The mean of analysts' price targets for Kymera Therapeutics (KYMR) points to a 34.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement am

Kymera Therapeutics, Inc. (NASDAQ:KYMR ) Q1 2024 Earnings Conference Call May 2, 2024 8:30 AM ET Company Participants Justine Koenigsberg - Vice President, Investor Relations Nello Mainolfi - Presiden

KT-474/SAR444656 (IRAK4) Phase 2 clinical trials ongoing in HS and AD  with data expected in the first half of 2025

Kymera Therapeutics (KYMR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

WATERTOWN, Mass., April 25, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using target

New preclinical data on novel E3 pairing and structural mechanisms for KT-333, a First-in-Class STAT3 degrader, presented in AACR's late-breaking poster session

Kymera Therapeutics' shares have dropped from $81 to $39 since my note back in 2021, but have risen >130% in the past 6m. The company's technology targets the ubiquitin proteasome system to degrade di